Villard J, Lisowska-Grospierre B, van den Elsen P, Fischer A, Reith W, Mach B
Department of Genetics and Microbiology, University of Geneva Medical School, Switzerland.
N Engl J Med. 1997 Sep 11;337(11):748-53. doi: 10.1056/NEJM199709113371104.
Major-histocompatibility-complex (MHC) class II deficiency is an autosomal recessive primary immunodeficiency disease in which MHC class II molecules are absent. It is a genetically heterogeneous disease of gene regulation resulting from defects in several transactivating genes that regulate the expression of MHC class II genes. The mutations responsible for MHC class II deficiency are classified according to complementation group (a group in which the phenotype remains uncorrected in pairwise fusions of cells). There are three known complementation groups (A, B, and C).
To elucidate the genetic defect in patients with MHC class II deficiency that was not classified genetically, we performed direct complementation assays with the three genes known to regulate the expression of MHC class II genes, CIITA, RFX5, and RFXAP, and the relevant mutations were identified in each patient.
Mutations in the RFXAP gene were found in three patients from unrelated families, and the resulting defect was classified as belonging to a novel complementation group (D). Transfection with the wild-type RFXAP gene restored the expression of MHC class II molecules in the patients' cells.
Mutations in a novel MHC class II transactivating factor, RFXAP, can cause MHC class II deficiency. These mutations abolish the expression of MHC class II genes and lead to the same clinical picture of immunodeficiency as in patients with mutations in the other two MHC class II regulatory genes.
主要组织相容性复合体(MHC)II类缺陷是一种常染色体隐性原发性免疫缺陷病,其中MHC II类分子缺失。它是一种基因调控的遗传异质性疾病,由调控MHC II类基因表达的几个反式激活基因缺陷引起。导致MHC II类缺陷的突变根据互补组分类(细胞两两融合时表型未校正的一组)。已知有三个互补组(A、B和C)。
为阐明未进行基因分类的MHC II类缺陷患者的基因缺陷,我们用三个已知调控MHC II类基因表达的基因CIITA、RFX5和RFXAP进行直接互补分析,并在每位患者中鉴定相关突变。
在来自无关家族的三名患者中发现RFXAP基因突变,所导致的缺陷被归类为属于一个新的互补组(D)。用野生型RFXAP基因转染可恢复患者细胞中MHC II类分子的表达。
一种新的MHC II类反式激活因子RFXAP中的突变可导致MHC II类缺陷。这些突变消除MHC II类基因的表达,并导致与其他两个MHC II类调控基因突变患者相同的免疫缺陷临床症状。